Evidence map›Paper›PMID 42231559›Full record

ArticleThoracic cancer2026

Single-Cell Analysis Identifies LYPD6B as a Tumor-Intrinsic Candidate Associated With Immunotherapy Nonresponse in Breast Cancer.

Yifei Wang, Haiwei Quan, Zhiguang Xu, Yixiang Wang, Zhibin Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yifei WangCenter for Cancer Immunotherapy of Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.ORCID https://orcid.org/0000-0002-6334-4244
Haiwei QuanDepartment of Biopharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology, Shenzhen, Guangdong, China.
Zhiguang XuDepartment of Biopharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology, Shenzhen, Guangdong, China.
Yixiang WangDepartment of Biopharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology, Shenzhen, Guangdong, China.
Zhibin WangCenter for Cancer Immunotherapy of Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.

Funding

National Key Research and Development Program of China 2023YFA0915700
6 · The paper itself

Abstract

Immune checkpoint blockade (ICB) induces durable responses in a subset of breast cancer patients, yet many show limited benefit from anti-PD-1/PD-L1 therapy. Understanding differences in the tumor microenvironment (TME) and tumor-intrinsic immune evasion between responders (R) and nonresponders (NR) is key to improving outcomes. We integrated three public scRNA-seq datasets from PD-(L)1-treated breast cancer (51 patients; 327022 cells) and analyzed paired pre-/posttreatment samples. Compared to NR, R patients exhibited increased CD8

Indexed as

Breast NeoplasmsImmunotherapySingle-Cell AnalysisFemaleHumansTumor Microenvironmentbreast cancerdrug repurposingimmunotherapy resistancePD‐1/PD‐L1single‐cell transcriptomics

Identifiers

PMID42231559
PMCPMC13240201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.